ClinicalTrials.gg

Program

CD8-guided IL-2 Fusion Protein AZD6750

Its studies are mostly in Melanoma, led by AstraZeneca.

Furthest: phase 2, since Jul 16, 20251 company-led study, 1 open or runningNext primary completion: Oct 2, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Jul 16, 2025Jul 16, 2025Oct 2, 2029phase 2 · NCT07115043
  • Named in AstraZeneca’s own pipeline as AZD6750, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2025First study: phase 2 study in MelanomaFirst studyNCT07115043 · 120 planned · United States, Australia, Japan and more

Ahead

  1. Oct 2, 2029Primary completion: phase 2 study in MelanomaNCT07115043

TargetBeta

“A recombinant fusion protein comprised of two CD8 binding domains and two IL-2 mutein domains, with potential immunostimulating and antineoplastic activities. Upon administration, CD8-guided IL-2 fusion protein AZD6750 specifically targets and preferentially binds, with its CD8 binding domains, t…”NCIt, read by Claude
“A recombinant fusion protein comprised of two CD8 binding domains and two IL-2 mutein domains, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07115043Melanoma · United States, Australia, Japan and more2RecruitingOct 2, 2029120

How it is read

Names in the registry

  • “AZD6750”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.